{"id":4203,"date":"2018-04-22T07:07:11","date_gmt":"2018-04-22T11:07:11","guid":{"rendered":"http:\/\/www.ipoboutique.com\/blog\/?p=4203"},"modified":"2018-04-22T07:07:11","modified_gmt":"2018-04-22T11:07:11","slug":"ipo-pipeline-update-new-filings-updated-terms-ending-4-20-18","status":"publish","type":"post","link":"https:\/\/www.ipoboutique.com\/blog\/ipo-pipeline-update-new-filings-updated-terms-ending-4-20-18\/","title":{"rendered":"IPO Pipeline Update – New Filings & Updated Terms (ending 4.20.18)"},"content":{"rendered":"

IPO Boutique keeps apprised of the active pipeline. Currently there are 63 active IPOs in the pipeline as of April 22, 2018. No SPACs or Unit Offerings are included. While the numbers may look diminished, we outlined why \u201clooks may be perceiving\u201d when it comes to the IPO pipeline\u00a0in this article.<\/strong><\/a><\/p>\n

\"Screen<\/a><\/p>\n

NEW FILINGS<\/strong><\/span><\/p>\n

Company: Evelo Biosciences, Inc.
\nSymbol: EVLO
\nDescription: Evelo Biosciences is discovering and developing potential therapies designed to act on the gut-body network.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): Morgan Stanley, Cowen, BMO Capital Markets
\nCo-Manager(s): JMP Securities
\nFiled: 4-13-18
\nListed Cash Raise: $100m<\/p>\n

Company: Adial Pharmaceuticals
\nSymbol: ADIL
\nDescription: They are a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder using their lead investigational new drug product, AD04, a selective serotonin-3 antagonist.
\nTrade Date: TBD
\nShares: 1.5 million
\nPrice Range: $5.00-$5.00
\nUnderwriter(s): Joseph Gunnar & Co.
\nTerms Added: 4-16-18
\nNote: Previously Postponed in February 2018<\/p>\n

Company: Pluralsight, Inc.
\nSymbol: PS
\nDescription: Pluralsight is an enterprise software company committed to closing the global technology skills gap.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): Morgan Stanley, J.P. Morgan, Barclays, BofA Merrill Lynch
\nCo-Manager(s): First Analysis Securities, Needham & Co., Raymond James, SunTrust Robinson Humphrey
\nTerms Added: 4-16-18
\nListed Cash Raise: $100m<\/p>\n

Company: The Lovesac Company
\nSymbol: LOVE
\nDescription: They are a technology driven, omni-channel company that designs, manufactures and sells unique, high quality furniture comprised of modular couches called Sactionals and premium foam beanbag chairs called Sacs.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): Roth Capital Partners
\nFiled: 4-20-18
\nListed Cash Raise: $46m<\/p>\n

TERMS ADDED<\/p>\n

Company: Smartsheet Inc.
\nSymbol: SMAR
\nDescription: They are a leading cloud-based platform for work execution, enabling teams and organizations to plan, capture, manage, automate, and report on work at scale, resulting in more efficient processes and better business outcomes.
\nShares: 11.6 million
\nPrice Range: $10.00-$12.00
\nTrade Date: 4\/27
\nUnderwriter(s): Morgan Stanley, J.P. Morgan, Jefferies, RBC Capital
\nCo-Manager: Canaccord Genuity, William Blair, SunTrust Robinson Humphrey
\nTerms Added: 4-16-18<\/p>\n

Company: nLIGHT, Inc.
\nSymbol: LASR
\nDescription: They are a leading provider of high-power semiconductor and fiber lasers.
\nTrade Date: 4\/27
\nShares: 5.4 million
\nPrice Range: $13.00-$15.00
\nUnderwriter(s): Stifel, Raymond James
\nCo-Manager(s): Needham & Co., Canaccord Genuity, D.A. Davidson
\nTerms Added: 4-16-18<\/p>\n

Company: Taiwan Liposome Company, Ltd.
\nSymbol: TLC
\nDescription: They are a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of best-in-class novel nanomedicines that combine our proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs).
\nTrade Date: 4\/26
\nShares: 4.7 million ($35m cash raise)
\nPrice Range: $7.46-$7.46
\nUnderwriter(s): Cantor
\nCo-Manager(s): CLSA, H.C. Wainwright, Janney Montgomery Scott, Laidlaw & Co. (UK) Ltd.
\nTerms Added: 4-16-18
\nNote: Their common shares are currently listed on the Taipei Exchange. On April 12, 2018, the last reported sale price of their common shares on the Taipei Exchange was NT$109.00 per share, or approximately $3.73 per share, equivalent to a price of $7.46 per ADS.<\/p>\n

Company: ASLAN Pharmaceuticals Limited
\nSymbol: ASLN
\nDescription: They are a clinical-stage oncology-focused biopharmaceutical company based in Singapore developing novel therapeutics for global markets. We target diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe.
\nShares: 7.5 million ADSs
\nPrice Range: $8.05-$8.05
\nTrade Date: 5\/3
\nUnderwriter(s): Leerink Partners, Piper Jaffray
\nCo-Manager: BTIG, H.C. Wainwright & Co., CLSA
\nTerms Added: 4-16-18
\nNote: Their ordinary shares are currently listed on the Taipei Exchange, or TPEx.<\/p>\n

Company: DocuSign, Inc.
\nSymbol: DOCU
\nDescription: DocuSign accelerates the process of doing business for companies, and simplifies life for their customers and employees.
\nShares: 21.7 million
\nPrice Range: $24.00-$26.00
\nTrade Date: 4\/27
\nUnderwriter(s): Morgan Stanley, J.P. Morgan, Citigroup, BofA Merrill Lynch, Deutsche Bank Securities
\nCo-Manager(s): JMP Securities, Piper Jaffray, William Blair
\nTerms Added: 4-17-18<\/p>\n

Company: Goosehead Insurance, Inc.
\nSymbol: GSHD
\nDescription: They are a leading independent personal lines insurance agency, based on personal lines revenue, reinventing the traditional approach to distributing personal lines products and services throughout the United States.
\nTrade Date: 4\/27
\nShares: 8.5 million
\nPrice Range: $14.00-$16.00
\nUnderwriter(s): J.P. Morgan, BofA Merrill Lynch
\nCo-Manager(s): Keefe Bruyette & Woods, William Blair
\nTerms Added: 4-17-18<\/p>\n","protected":false},"excerpt":{"rendered":"

IPO Boutique keeps apprised of the active pipeline. Currently there are 63 active IPOs in the pipeline as of April 22, 2018. No SPACs or Unit Offerings are included. While the numbers may look diminished, we outlined why \u201clooks may be perceiving\u201d when it comes to the IPO pipeline\u00a0in this article. NEW FILINGS Company: Evelo[…]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[24],"tags":[],"class_list":["post-4203","post","type-post","status-publish","format-standard","hentry","category-ipo"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4203","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=4203"}],"version-history":[{"count":1,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4203\/revisions"}],"predecessor-version":[{"id":4205,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4203\/revisions\/4205"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=4203"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=4203"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=4203"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}